GSK schedules third-quarter results. GSK stock stands at EUR 22.87 before October 28

Published on 10/27/2026 at 10:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK's October 26 cancer data showed a 76 percent response rate. GSK stock costs EUR 22.87 on October 27, 2026, 0.09 percent above Xetra close.

Results and pipeline evidence

GSK reported a 76 percent complete response rate in October 2026 cancer data.
Third-quarter turnover is forecast at GBP 8.84 billion versus GBP 8.55 billion a year earlier.
GSK stock trades at EUR 22.87 at 10:44 a.m. CEST at Lang & Schwarz on October 27, 2026, 0.09 percent above the Xetra close of October 26, 2026.
Jefferies maintained a GBp 2,500.00 target on October 19, 2026.

GSK, GB00BN7SWP63, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) stock was trading at EUR 22.87 at Lang & Schwarz on October 27, 2026 at 10:44 a.m. CEST, plus 0.09 percent versus the Xetra close of October 26, 2026 (EUR 22.85). The latest company catalyst was positive cancer data released on October 26, while the next quarterly report is scheduled for October 28.

According to FinanzNachrichten, GSK said interim data from the AZUR-1 phase II trial showed a 76 percent complete response rate for Jemperli in adults with locally advanced rectal cancer. The same update gave Mo-Rez an objective response rate of 62 percent in platinum-resistant ovarian cancer after more than 13 months of follow-up.

Results arrive on October 28

GSK has scheduled its third-quarter 2026 results for October 28. The company said its second-quarter 2026 revenue was GBP 8.41 billion in the reported financial period, while standardized financial data put operating profit at GBP 481.0 million and diluted earnings per share at GBP 0.21.

For the coming report, MarketWatch cited company-compiled consensus for third-quarter turnover of GBP 8.84 billion, versus GBP 8.55 billion in the third quarter of 2025. Core operating profit is forecast at GBP 2.93 billion, compared with GBP 2.99 billion a year earlier.

What does the pipeline mean?

The pipeline update offers a quantified counterweight to the earnings debate. GSK's October 26 data included a 62 percent response rate for Mo-Rez, while the company is also targeting cost savings of GBP 1.9 billion by 2029 under its strategy reset, according to MarketWatch.

Three dates frame the story

On July 28, 2026, GSK reported second-quarter revenue of GBP 8.41 billion. On October 21, 2026, Proactive reported that Jefferies retained a Buy rating and a GBp 2,500.00 target after Hibsago won US approval. On October 26, 2026, GSK disclosed the AZUR-1 response rate of 76 percent.

Dates for the next decision points

The next reporting date is October 28, 2026, for third-quarter results, according to GSK. The following scheduled earnings date is February 3, 2027, according to Moomoo.

Stock holds near the Xetra close

At EUR 22.87, the Lang & Schwarz quote was EUR 0.02 above the Xetra close of October 26, 2026, a difference of 0.09 percent. The small spread leaves the October 28 results as the next concrete test for the earnings outlook. The further course of trading is shown by the continuously updated real-time quote of GSK stock.